Stockscreener 앱 받기
5.67
2.03%
-0.1173
시간 외 거래:
5.79
0.12
+2.12%
전일 마감가:
$5.7873
열려 있는:
$5.8
하루 거래량:
1,188
Relative Volume:
0.11
시가총액:
$56.61M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-0.53%
1개월 성능:
+8.00%
6개월 성능:
-7.20%
1년 성능:
+0.00%
1일 변동 폭
$5.5289
$5.80
1주일 범위
$5.12
$6.61
52주 변동 폭
$3.81
$10.28
Serina Therapeutics Inc Stock (SER) Company Profile
명칭
Serina Therapeutics Inc
전화
(256) 327-9630
주소
601 GENOME WAY, HUNTSVILLE
SER을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
5.67 | 56.61M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Serina Therapeutics Inc 주식(SER)의 최신 뉴스
Serina Therapeutics to Present at JonesResearch Virtual CNS Day - The Manila Times
Serina Therapeutics CEO to Showcase Revolutionary CNS Drug Technology: Key Presentation Details Revealed - Stock Titan
Serina Therapeutics Says May Offer And Sell Shares Of Common Stock Of Up To $13.3 Million - marketscreener.com
Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients - The Globe and Mail
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit - GlobeNewswire
Revolutionary Drug Delivery Tech Could Make mRNA Vaccines Safer: New Trial Data - Stock Titan
Serina Therapeutics closes $5 million funding for Parkinson’s trial By Investing.com - Investing.com Canada
Serina Therapeutics Secures $5 Million Funding - MarketScreener
Serina Therapeutics closes $5 million funding for Parkinson’s trial - Investing.com
Serina Therapeutics Secures $5 Million in Funding to - GlobeNewswire
Revolutionary Parkinson's Treatment Gets $5M Boost: Serina's New Drug Heads to Clinical Trials - Stock Titan
Serina Therapeutics to Present at the Jones Healthcare and Technology Innovation Conference - GlobeNewswire
Serina's Game-Changing POZ Platform Takes Center Stage at Major Healthcare Conference - Stock Titan
Serina Therapeutics Files For Mixed Shelf Of Upto $100 MillionSEC Filing - MarketScreener
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Serina Therapeutics to Present Novel Data on Non-Immunogenic Lipid Nanoparticles at ACS Spring 2025 Meeting - Nasdaq
Serina Therapeutics to Present at the American Chemistry Society (ACS) Spring 2025 Meeting - GlobeNewswire
Serina Cuts $11.2M Debt, Secures $10M Investment While Revenue Drops 98% - Stock Titan
Jones Trading Initiates Coverage of Serina Therapeutics (SER) with Buy Recommendation - Nasdaq
Serina Therapeutics initiated with a Buy at JonesResearch - TipRanks
Serina Therapeutics Appoints Dr. Venkatesan to Board - TipRanks
Serina Therapeutics Appoints Dr. Jay Venkatesan to Board of Directors - Nasdaq
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors - GlobeNewswire
Former Alpine Immune Sciences Founder Who Led $4.9B Exit Takes Board Seat at Serina - StockTitan
Huntsville biotech firm partnering with Pfizer lands $10 million for Parkinson’s trial - MSN
Serina secures additional $5 million for Parkinson's trial - MSN
Serina secures additional $5 million for Parkinson's trial By Investing.com - Investing.com Australia
Stocks to Watch: Palantir Technologies, Synaptics, J&J Snack Foods, Serina Therapeutics - MarketWatch
Serina Therapeutics's Shares Up Following $5M of Equity Financing - MarketWatch
Serina Therapeutics Receives Second $5 Mln Tranche To Strengthen Cash Position - Marketscreener.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Serina Therapeutics receives funding to advance SER-252 into clinical trial - TipRanks
Serina Therapeutics Secures $5 Million for SER-252 Trials - TipRanks
Serina Therapeutics Receives Second $5 Million Tranche to - GlobeNewswire
Parkinson's Breakthrough: Serina Therapeutics Lands Premium-Priced $5M Investment to Advance Novel Treatment - StockTitan
Serina Therapeutics Secures Additional $5 Million Financing to Advance SER-252 into Phase 1 Trial for Advanced Parkinson's Disease - Nasdaq
Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics - MarketWatch
Serina Therapeutics Shares Rise After Sale of UniverXome Subsidiary - MarketWatch
Serina Therapeutics Sells UniverXome Subsidiary - MarketWatch
Serina Therapeutics Announces Sale of UniverXome Subsidiary - GlobeNewswire
Serina Therapeutics Achieves Debt-Free Status After $11.2M UniverXome Sale, Sharpens Focus on Parkinson's Drug - StockTitan
Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors - GlobeNewswire
Serina Therapeutics, Inc. Appoints Karen J. Wilson to its Board of Directors -January 14, 2025 at 05:25 pm EST - Marketscreener.com
Serina Therapeutics director Bailey Gregory buys shares worth $17,744 By Investing.com - Investing.com Australia
Serina Therapeutics director Bailey Gregory buys shares worth $17,744 - Investing.com
Serina Therapeutics expands equity incentive plan By Investing.com - Investing.com Australia
Serina Therapeutics expands equity incentive plan - Investing.com India
Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024 - The Globe and Mail
Serina Therapeutics to Present at Tribe Public’s Webinar - GlobeNewswire
Serina Therapeutics to Unveil Breakthrough Parkinson's Treatment Strategy in Upcoming Webinar - StockTitan
Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit - GlobeNewswire
Serina Therapeutics Inc (SER) 재무 분석
Serina Therapeutics Inc (SER)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):